JP5687425B2 - 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤 - Google Patents

肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤 Download PDF

Info

Publication number
JP5687425B2
JP5687425B2 JP2009514226A JP2009514226A JP5687425B2 JP 5687425 B2 JP5687425 B2 JP 5687425B2 JP 2009514226 A JP2009514226 A JP 2009514226A JP 2009514226 A JP2009514226 A JP 2009514226A JP 5687425 B2 JP5687425 B2 JP 5687425B2
Authority
JP
Japan
Prior art keywords
antibody
subunit
drug
treatment
insulin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009514226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539827A5 (cg-RX-API-DMAC7.html
JP2009539827A (ja
Inventor
オレグ イリッチ エプシュテイン
オレグ イリッチ エプシュテイン
スベトラーナ アレクサンドロブナ セルゲーエバ
スベトラーナ アレクサンドロブナ セルゲーエバ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2006119655/15A external-priority patent/RU2438707C2/ru
Priority claimed from RU2006119658/15A external-priority patent/RU2437678C2/ru
Application filed by Individual filed Critical Individual
Publication of JP2009539827A publication Critical patent/JP2009539827A/ja
Publication of JP2009539827A5 publication Critical patent/JP2009539827A5/ja
Application granted granted Critical
Publication of JP5687425B2 publication Critical patent/JP5687425B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009514226A 2006-06-06 2007-05-31 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤 Expired - Fee Related JP5687425B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2006119655/15A RU2438707C2 (ru) 2006-06-06 2006-06-06 Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
RU2006119658 2006-06-06
RU2006119658/15A RU2437678C2 (ru) 2006-06-06 2006-06-06 Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2006119655 2006-06-06
PCT/RU2007/000288 WO2007149010A1 (en) 2006-06-06 2007-05-31 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Publications (3)

Publication Number Publication Date
JP2009539827A JP2009539827A (ja) 2009-11-19
JP2009539827A5 JP2009539827A5 (cg-RX-API-DMAC7.html) 2013-03-21
JP5687425B2 true JP5687425B2 (ja) 2015-03-18

Family

ID=38833657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514226A Expired - Fee Related JP5687425B2 (ja) 2006-06-06 2007-05-31 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤

Country Status (11)

Country Link
US (2) US9308259B2 (cg-RX-API-DMAC7.html)
EP (2) EP2395021A1 (cg-RX-API-DMAC7.html)
JP (1) JP5687425B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090024241A (cg-RX-API-DMAC7.html)
AU (1) AU2007261782A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712540A2 (cg-RX-API-DMAC7.html)
CA (1) CA2654408C (cg-RX-API-DMAC7.html)
EA (1) EA200802440A1 (cg-RX-API-DMAC7.html)
IL (2) IL195755A (cg-RX-API-DMAC7.html)
MX (1) MX2008015621A (cg-RX-API-DMAC7.html)
WO (1) WO2007149010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
CA2804966A1 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
RU2610438C2 (ru) * 2011-06-02 2017-02-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
ES2425314R1 (es) * 2010-07-15 2014-07-09 Oleg Iliich Epshtein Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario
SE1350212A1 (sv) * 2010-07-21 2013-04-22 Oleg Iliich Epshtein Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
PE20130387A1 (es) * 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 一価抗原結合タンパク質
WO2012130872A1 (en) * 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
RU2603623C2 (ru) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты)
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP4194001B1 (en) 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment of type 2 diabetes and obesity
JP2018532693A (ja) 2015-08-06 2018-11-08 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
JPS61176534A (ja) * 1985-01-30 1986-08-08 Takashi Muramatsu 避妊用剤
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US6803452B2 (en) 1991-02-26 2004-10-12 New York University RPTP-β antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
AU1812595A (en) 1994-02-28 1995-09-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
US5861266A (en) 1994-02-28 1999-01-19 New York University Treatment of diabetes mellitus and insulin receptor signal transduction
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
WO1997028776A1 (en) 1996-02-12 1997-08-14 Oleg Iliich Epshtein Medicament and method of treating an organism with medicaments
US5726027A (en) * 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
RU2114646C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Способ повышения защитных свойств организма при воздействии внешних физических факторов
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
RU2144370C1 (ru) 1999-01-06 2000-01-20 Титиева Наталья Михайловна Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы
RU2161955C1 (ru) 1999-07-16 2001-01-20 Эпштейн Олег Ильич Способ изменения физико-химических или физико-химических и биологических свойств вещества
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US20040198648A1 (en) 2000-10-27 2004-10-07 George Grunberger Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
RU2199345C1 (ru) * 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
AUPS019802A0 (en) * 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
WO2004012765A1 (fr) 2002-08-02 2004-02-12 Oleg Iliich Epshtein Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
SE1350212A1 (sv) * 2010-07-21 2013-04-22 Oleg Iliich Epshtein Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar

Also Published As

Publication number Publication date
EP2036574A4 (en) 2009-07-01
US20160159916A1 (en) 2016-06-09
CA2654408C (en) 2018-05-08
WO2007149010A1 (en) 2007-12-27
IL195755A0 (en) 2011-08-01
EP2036574A1 (en) 2009-03-18
MX2008015621A (es) 2009-03-06
EP2395021A1 (en) 2011-12-14
EA200802440A1 (ru) 2009-06-30
US9308259B2 (en) 2016-04-12
US20110008452A1 (en) 2011-01-13
KR20090024241A (ko) 2009-03-06
IL246402A (en) 2017-12-31
IL195755A (en) 2016-07-31
JP2009539827A (ja) 2009-11-19
AU2007261782A1 (en) 2007-12-27
CA2654408A1 (en) 2007-12-27
BRPI0712540A2 (pt) 2012-10-16

Similar Documents

Publication Publication Date Title
JP2009539827A (ja) 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤
JP2009539827A5 (cg-RX-API-DMAC7.html)
US20070141058A1 (en) Method of correcting immunopathological reactions and a medicament
EA029400B1 (ru) Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
AU2006340119A1 (en) Solid oral form of a medicinal preparation and a method for the production thereof
US8178498B1 (en) Medicament and method of treating an organism with medicaments
CN101495143A (zh) 用于治疗肥胖、糖尿病和与受损的葡萄糖耐受性有关的疾病的药物制剂
JP7190571B2 (ja) ブレイアコニチンaの用途
US10213486B2 (en) Formulations of diluted amino acid segments and methods for making same
RU2129005C1 (ru) Сбор для восстановления функции щитовидной железы
CN103272083A (zh) 用于预防和/或治疗哮喘的药物组合物、其制备方法及用途
JP5480139B2 (ja) 食欲制御用化合物
RU2437678C2 (ru) Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
CN101549020B (zh) 无糖型枫蓼颗粒制剂、其用途及制备方法
RU2228198C1 (ru) Способ коррекции патологического аутоиммунного процесса при сахарном диабете
CN101695507B (zh) 一种治疗糖尿病的药物
RU2245157C2 (ru) Биологически активная добавка для профилактики и лечения гриппа "фитогриппин"
CN103181945A (zh) 丝瓜子的新用途
CN106822234A (zh) 一种治疗高血压的中西药组合物及其制备方法
CN118286156A (zh) 减重多肽药物组合物、鼻喷剂及其制备方法
RU2552221C2 (ru) Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
JPH02142732A (ja) 肥満並びに肥満に関連する各種疾患の治療剤
CN101380364A (zh) 用于糖尿病患者的草药产品及其生产方法
CN114163469A (zh) 美索巴莫磷酸钠新药族药品的剂型
Harika et al. SEMAGLUTIDE: A TRUE G

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121029

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150122

R150 Certificate of patent or registration of utility model

Ref document number: 5687425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees